| Scott H Johnson, MD | |
|
1835 Pearl St, Eugene, OR 97401-8217 | |
| (541) 687-1668 | |
| (541) 684-3061 |
| Full Name | Scott H Johnson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 1835 Pearl St, Eugene, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093785149 | NPI | - | NPPES |
| 081351 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD18824 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cascade Health Solutions | Eugene, OR | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Healthcare Resources Llc | 4486835477 | 129 |
News Archive
EKF Diagnostics, announces the availability of a liquid, enzymatic test for glycated albumin that was recently FDA cleared for sales in the U.S.
ZIOPHARM Oncology, Inc., a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company's continued progress with its clinical programs.
Although it is "easy to hoot with derision" at the "awfully complicated positions" on abortion rights taken by former New York City Mayor Rudolph Giuliani (R) and former Massachusetts Gov. Mitt Romney (R), the two possible Republican presidential candidates "make sense" when listened to "with a decent sympathy," Ann Althouse, a law professor at the University of Wisconsin, writes in a New York Times opinion piece.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.
› Verified 8 days ago
| Entity Name | Oregon Healthcare Resources Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982907572 PECOS PAC ID: 4486835477 Enrollment ID: O20110223001220 |
News Archive
EKF Diagnostics, announces the availability of a liquid, enzymatic test for glycated albumin that was recently FDA cleared for sales in the U.S.
ZIOPHARM Oncology, Inc., a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company's continued progress with its clinical programs.
Although it is "easy to hoot with derision" at the "awfully complicated positions" on abortion rights taken by former New York City Mayor Rudolph Giuliani (R) and former Massachusetts Gov. Mitt Romney (R), the two possible Republican presidential candidates "make sense" when listened to "with a decent sympathy," Ann Althouse, a law professor at the University of Wisconsin, writes in a New York Times opinion piece.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott H Johnson, MD Po Box 1648, Eugene, OR 97440-1648 Ph: (541) 687-1668 | Scott H Johnson, MD 1835 Pearl St, Eugene, OR 97401-8217 Ph: (541) 687-1668 |
News Archive
EKF Diagnostics, announces the availability of a liquid, enzymatic test for glycated albumin that was recently FDA cleared for sales in the U.S.
ZIOPHARM Oncology, Inc., a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company's continued progress with its clinical programs.
Although it is "easy to hoot with derision" at the "awfully complicated positions" on abortion rights taken by former New York City Mayor Rudolph Giuliani (R) and former Massachusetts Gov. Mitt Romney (R), the two possible Republican presidential candidates "make sense" when listened to "with a decent sympathy," Ann Althouse, a law professor at the University of Wisconsin, writes in a New York Times opinion piece.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.
› Verified 8 days ago
Dr. Rebecca Trojan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2830 Crescent Ave, Eugene, OR 97408 Phone: 541-686-9000 Fax: 541-242-4585 | |
John R Lebow, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1755 Coburg Rd Ste 301, Eugene, OR 97401 Phone: 541-344-8225 Fax: 541-744-7322 | |
Stephan M Schepergerdes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4135 Quest Dr, Eugene, OR 97402 Phone: 541-461-8006 Fax: 541-463-2197 | |
Dr. Gerald Joseph Fleischli, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1232 University Of Oregon, University Of Oregon Health Center, Eugene, OR 97403 Phone: 541-346-0565 | |
Trek Lyons, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Coburg Rd, Eugene, OR 97401 Phone: 541-485-8111 | |
Donna M Byrne, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4135 Quest Dr, Eugene, OR 97402 Phone: 541-461-8006 Fax: 541-463-2197 | |
Dr. Rachel Jean Nosce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 598 E 13th Ave, Eugene, OR 97401 Phone: 541-640-7625 |